The prognostic impact of left ventricular thrombus resolution after acute coronary syndrome and risk modulation via antithrombotic treatment strategies.

Abstract

BACKGROUND\nLeft ventricular thrombus (LVT) is a rare but dreaded complication during the acute phase of acute coronary syndrome (ACS). However, profound data on long-term outcome and associated antithrombotic treatment strategies of this highly vulnerable patient population are scarce in current literature.\n\n\nMETHODS\nPatients presenting with ACS were screened for presence of LVT and subsequently included within a prospective clinical registry. All-cause mortality and the composite of major adverse cardiac events (MACE) and thromboembolic events were defined as primary and secondary endpoint.\n\n\nRESULTS\nWithin 43 patients presenting with LVT, thrombus resolution during patient follow-up was observed in 27 individuals (62.8%). Patients that reached a resolution of LVT experienced lower incidence rates of death (-23.9%; p\xa0=\xa0.022), MACE (-37.8%; p\xa0=\xa0.005), and thromboembolic events (-35.2%; p\xa0=\xa0.008). Even after adjustment for clinical variables, thrombus resolution showed an independent inverse association with all-cause death with a hazard ratio (HR) of 0.14 (95% CI: 0.03-0.75; p\xa0=\xa0.021) and as well with MACE with a HR of 0.22 (95% CI: 0.07-0.68; p\xa0=\xa0.008) and thromboembolic events with a HR of 0.22 (95% CI: 0.06-0.75; p\xa0=\xa0.015). Triple antithrombotic therapy (TAT) with ticagrelor/prasugrel showed a strong and independent association with thrombus resolution with an adjusted HR of 3.25 (95% CI: 1.22-8.68; p\xa0=\xa0.019) compared to other strategies.\n\n\nCONCLUSION\nThe presented data indicate a poor outcome of ACS patients experiencing LVT. In terms of a personalized risk stratification, thrombus resolution has a strong protective impact on both all-cause death and MACE with the potential to tailor treatment decisions-including an intensified antithrombotic treatment approach-in this patient population.